Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | BPTF | Q12830 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2272061 | 0.80 | MAPK1 (0.37) | HRH4MEN1KMT2AACHEMAPK1 | |
| SCHEMBL18711733 | 0.75 | GAA (0.41) | MEN1KMT2AACHEMAPK1BPTF | |
| SCHEMBL2272015 | 0.70 | HTR2A (0.40) | MEN1KMT2AACHEMAPK1BPTF | |
| SCHEMBL11348979 | 0.68 | HRH4 (0.44) | HRH4MEN1KMT2AHTR3A | |
| SCHEMBL30350953 | 0.68 | ACHE (0.43) | MEN1KMT2AACHEMAPK1BPTF | |
| SCHEMBL1821069 | 0.68 | ACHE (0.43) | MEN1KMT2AACHEMAPK1BPTF | |
| SCHEMBL11351061 | 0.66 | NPSR1 (0.37) | MEN1KMT2AMAPK1ALDH1A1TSHR | |
| SCHEMBL21573227 | 0.66 | HRH4 (0.39) | HRH4ALDH1A1TSHRHTR3A | |
| SCHEMBL2118395 | 0.66 | HRH4 (0.39) | HRH4ALDH1A1TSHRHTR3A | |
| SCHEMBL7354776 | 0.66 | HRH4 (0.46) | HRH4MEN1KMT2AALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989463-B2 | Biccyclic compounds as GATA modulators | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-08-02 | — | — | US | disclosed |
| US-20100144731-A1 | Novel Biccyclic Compounds As GATA Modulators | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| WO-2010028174-A1 | NOVEL BICCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144731-A1 | Novel Biccyclic Compounds As GATA Modulators | GATAD2A, GATAD2B, RUNX1 | HRH4 1956/4885MEN1 4331/4885KMT2A 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.